Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma.
Journal: Molecular cancer therapeutics
Published: March 19, 2025
Investigation of Cell Mechanics and Migration on DDR2-Expressing Neuroblastoma Cell Line.
Journal: Life (Basel, Switzerland)
Published: September 13, 2024
A Novel Druggable Dual-Specificity tYrosine-Regulated Kinase3/Calmodulin Kinase-like Vesicle-Associated Signaling Module with Therapeutic Implications in Neuroblastoma.
Journal: Biomedicines
Published: December 19, 2023
Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis.
Journal: Molecular cancer therapeutics
Published: October 25, 2023
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology.
Journal: Cancer metastasis reviews
Published: August 26, 2021
PRMT5 activates AKT via methylation to promote tumor metastasis.
Journal: Nature communications
Published: October 26, 2020
KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma.
Journal: Nature communications
Published: June 22, 2020
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Journal: Pediatric blood & cancer
Published: March 09, 2020
Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Journal: Oncotarget
Published: July 26, 2018
Last Updated: 09/26/2026